Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

AIDS

Volumn 25, Issue 10, 2011, Pages 1271-1280

  Yuan, Jing ^a,d   Guo, Sheng ^a   Hall, David ^b   Cammett, Anna M ^c   Jayadev, Supriya ^d   Distel, Manuel ^e   Storfer, Stephen ^c   Huang, Zimei ^a   Mootsikapun, Piroon ^f   Ruxrungtham, Kiat ^g   Podzamczer, Daniel ^h   Haas, David W ⁱ  

^a Non Clinical Drug Safety   (United States)

^b Biometrics and Data Management   (United States)

^c Medical Affairs Virology   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f KHON KAEN UNIVERSITY   (Thailand)

^g CHULALONGKORN UNIVERSITY   (Thailand)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2B6; HIV; human leukocyte antigen; nevirapine; pharmacogenomics; rash; toxicogenomics

Indexed keywords

ABACAVIR; CYTOCHROME P450 2B6; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; NEVIRAPINE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; AFRICA; ALLELE; ARTHRALGIA; ARTICLE; ASIAN; CD4 LYMPHOCYTE COUNT; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG METABOLISM; EUROPE; FEMALE; FLU LIKE SYNDROME; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MYALGIA; NEGRO; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; RACE; RASH; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY;

EID: 85027929582     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834779df     Document Type: Article

References (28)

1. Leith J, Piliero P, Storfer S, Mayers D, Hinzmann R. Appropriate use of nevirapine for long-term therapy. J Infect Dis 2005; 192:545-546.
2. Boehringer-Ingelheim Pharmaceuticals Inc. Viramune(nevira-pine) prescribing information. 2009. http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=re-netnt&folderPath=/Prescribingmune. pdf. [Accessed 31 January 2011]
3. Hoskins JM, Roederer MW, McLeod HL. Nevirapine hypersen-sitivity reaction: will the real HLA please stand up? Curr Opin Mol Ther 2009; 11:226-230.
4. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1M0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19:97-99. (Pubitemid 40111026)
5. Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007; 21:264-265. (Pubitemid 46036947)
6. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20:1621-1626. (Pubitemid 44162404)
7. Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43:783-786. (Pubitemid 44330746)
8. Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, Altan AM, et al. Nevirapine-induced hepatotoxicity and pharmaco-genetics: a retrospective study in a population from Mozambique. Pharmacogenomics 2010; 11:23-31.
9. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, et al. CYP2B6 genetic variants are associated with nevir-apine pharmacokinetics and clinical response in HIV-1-in-fected children. AIDS 2007; 21:2191-2199. (Pubitemid 350287217)
10. Chantarangsu S, Cressey TR, Mahasirimongkol S, Capparelli E, Tawon Y, Ngo-Giang-Huong N, et al. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J Antimicrob Chemother 2009; 64:1265-1273.
11. Mahungu T, Smith C, Turner F, Egan D, Youle M, Johnson M, et al. Cytochrome P450 2B6 516G
12. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007; 8:86-91. (Pubitemid 46390844)
13. Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, et al. Impact of CYP2B6 983T>C polymorphism on nonnucleoside reverse transcriptase inhibitor plasma concentrations inHIV-infected patients. J Antimicrob Chemother 2008; 61:914-918. (Pubitemid 351436194)
14. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and ne-virapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15:1-5. (Pubitemid 43205520)
15. Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E, et al. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 2010; 54:4432-4439.
16. Likanonsakul S, Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W, Tunthanathip P, et al. HLA-CwM04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther 2009; 6:22.
17. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertibur-anakul S, Sungkanuparph S, Manosuthi W, et al. HLA-BM3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009; 19:139-146.
18. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29:306-309. (Pubitemid 33096456)
19. National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS (DAIDS). Division of AIDS table for grading severity of adult adverse experiences. 1992. http://rsc.tech-res. com/Document/safetyandpharmacovigilance/ Table-for-Grading-Severity-of-Adult-AEs-v01a.pdf. [Accessed 31 January 2011]
20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. In: Am J Human Genet 2007; 81:559-575. http://pngu.mgh.harvard.edu/ purcell/plink/. [Accessed 28 January 2011] (Pubitemid 47330214)
21. Purcell S. PLINK version 1.06. 2009. http://pngu.mgh.harvard. edu/purcell/plink/. [Accessed 28 January 2011]
22. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27: 1488-1495.
23. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999; 27:895-901; [Accessed January 31, 2011]. (Pubitemid 29347589)
24. Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005; 10:489-498. (Pubitemid 41059195)
25. Chen J, Mannargudi BM, Xu L, Uetrecht J. Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem Res Toxicol 2008; 21:1862-1870.
26. Walubo A, Barr S, Abraham AM. RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Methods Find Exp Clin Pharmacol 2006; 28:423-431. (Pubitemid 44568618)
27. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acid Res 2011; 39:D913-D919. http://www.allelefrequencies. net. [Accessed 31 January 2011]
28. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38 (Suppl 2):S80-S89. (Pubitemid 38328169)